The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study

Schizophrenia Research

Volumn 93, Issue 1-3, 2007, Pages 109-116

  Zoccali, R ^a   Muscatello, M R ^a   Bruno, A ^a   Cambria, R ^a   Mico U ^a   Spina, E ^b   Meduri, M ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Augmentation; Clozapine; Lamotrigine; Resistant; Schizophrenia; Treatment

Indexed keywords

CLOZAPINE; LAMOTRIGINE; LORAZEPAM; PLACEBO;

ADD ON THERAPY; ADULT; AGITATION; ARTICLE; ATTENTION; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; ITALY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOTOR PERFORMANCE; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; VERBAL BEHAVIOR;

ADULT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; ATTENTION; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; TRIAZINES;

EID: 34249323746     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.02.009     Document Type: Article

References (37)

1. Addington D., Addington J., and Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry 163 Suppl. 22 (1993) 39-44
2. Anand A., Charney D.S., Oren D.A., Berman R.M., Hu X.S., Cappiello A., and Krystal J.H. Attenuation of neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Arch. Gen. Psychiatry 57 (2000) 270-276
3. Andreasen N. Scale for the assessment of Negative Symptoms (SANS) (1983), University of Iowa, Iowa
4. Andreasen N. Scale for the assessment of Positive Symptoms (SAPS) (1984), University of Iowa, Iowa
5. Calabrese J.R., Sullivan J.R., Bowden C.L., Suppes T., Goldberg G.F., and Sachs G.S. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J. Clin. Psychiatry 63 (2002) 1012-1019
6. Chan Y.C., Miller K.M., Shaheen N., Votolato N.A., and Hankins M.B. Worsening of psychotic symptoms in schizophrenia with addition of lamotrigine: a case report. Schizophr. Res. 78 2-3 (2005) 343-345
7. Dursun S.M., and Deakin J.F.W. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome studies. J. Psychopharmacol. 15 (2001) 297-301
8. Dursun S.M., McIntosh D., and Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch. Gen. Psychiatry 56 (1999) 950
9. Gluck M.R., Thomas R.G., Davis K.L., and Haroutounian V. Increased phosphate-activated glutaminase and glutamic acid decarboxylase activities in dorsolateral prefrontal cortex of aged schizophrenics: altered glutamate and GABA metabolism in schizophrenia. Am. J. Psychiatry 159 (2002) 1165-1173
10. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158 (2001) 1367-1377
11. Halberstadt A.L. The phencyclidine-glutamate model of schizophrenia. Clin. Neuropharmacol. 18 3 (1995) 237-249
12. Haroutunian V., Dracheva S., and Davis K. Neurobiology of glutamatergic abnormalities in schizophrenia. Clin. Neurosci. Res. 3 (2003) 67-76
13. Heaton R., Chelune G., Talley J., Kay G., and Curtis G. Wisconsin Card Sorting Test manual (1993), Psychological Resources, Odessa, FL
14. Holzer L., and Halfon O. Normalization of impaired cognitive functions failed to improve clinical symptomatology in a schizophrenic patient. Eur. Psychiatr. 19 (2004) 384-386
15. Hurley S.C. Lamotrigine update and its use in mood disorders. Ann. Pharmacother. 36 (2002) 860-873
16. Ishimaru M., Kurumaji A., and Toro M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol. Psychiatry 35 (1994) 84-89
17. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
18. Kalyoncu A., Mirsal H., Pektas{dot below} Ö., Ünsalan N., Tan D., and Beyazyürek M. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect?. Psychopharmacology 19 3 (2005) 301-305
19. Kim J.S., Kornhuber H.H., Scmid-Burgk W., and Holzmuller B. Low cerebrospinal glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20 (1980) 379-382
20. Kolivakis T.T., Beauclair L., Margolese H.C., and Chouinard G. Long-term lamotrigine adjunctive to antipsychotic monotherapy in schizophrenia: further evidence. Can. J. Psychiatry 49 4 (2004) 280
21. Kossen M., Selten J.P., and Kahn R.S. Elevated clozapine plasma level with lamotrigine. Am. J. Psychiatry 158 (2001) 1930
22. Kremer I., Vass A., Gorelik I., Bar G., Blanaru M., Javitt D.C., and Heresco-Levy U. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol. Psychiatry 56 (2004) 441-446
23. Labiner M. Lamotrigine and rash: scratching beneath the surface. J. Clin. Psychiatry 63 (2002) 1010-1011
24. Large C.H., Webster E.L., and Goff D.C. The potential role of lamotrigine in schizophrenia. Psychopharmacology 181 3 (2005) 415-436
25. Munro J., Matthiasson P., Osborne S., Travis M., Purcell S., Cobb A.M., Launer M., Beer M.D., and Kerwin R. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr. Scand. 110 (2004) 292-298
26. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 10 (1962) 799-812
27. Premkumar, T.S., Pick, J., 2006. Lamotrigine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD005962. 10.1002/14651858.CD005962. pub2.
28. Saba G., Dumortier G., Kalalou K., Benadhira R., Degrassat K., Glikman J., and Januel D. Lamotrigine and clozapine combination in refractory schizophrenia: three cases. J. Neuropsychiatry Clin. Neurosci. 14 (2002) 86
29. Simpson M.D., Slater P., and Deakin J.F. Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia. Biol. Psychiatry 44 (1998) 423-427
30. Spina E., D'Arrigo C., Migliardi G., Santoro V., Muscatello M.R., Micò U., D'Amico G., and Perucca E. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther. Drug. Monit. 28 5 (2006) 599-602
31. Spreen O., and Benton A.L. Neurosensory Center Comprehensive Examination For Aphasia (NCCEA) (1977), University of Victoria Neuropsychology Laboratory, Victoria
32. Szegedi A., Anghelescu I., Wiesner J., Schlegel S., Weigmann H., Hartter S., Hiemke C., and Wetzel H. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32 4 (1999) 148-153
33. Tamminga C.A. Glutamatergic aspects of schizophrenia. Br. J. Psychiatry 174 (1999) 12-15
34. Tamminga C.A., and Holcomb H.H. Phenotype of schizophrenia: a review and formulation. Mol. Psychiatry 10 (2005) 27-39
35. Thomas R., Howe V., Foister K., and Keks N. Adjunctive lamotrigine in treatment-resistant schizophrenia. Int. J. Psychopharmacology 9 (2006) 125-127
36. Tiihonen J., Hallikainen T., Ryynänen O.-P., Repo-Tiihonen E., Kotilainen I., Eronen M., Toivonen P., Wahlbeck K., and Putkonen A. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol. Psychiatry 54 (2003) 1241-1248
37. Trenerry M.R., Crosson B., DeBoe J., and Leber W.R. Stroop Neuropsychological Screening Test (1989), Psychological Assessment Resources, Inc., Odessa FL